147 filings
8-K
ZSANQ
Zosano Pharma Corp
3 Jun 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:01am
8-K
ZSANQ
Zosano Pharma Corp
2 Jun 22
Termination of a Material Definitive Agreement
8:35am
8-K
ZSANQ
Zosano Pharma Corp
18 May 22
Departure of Directors or Certain Officers
8:00am
8-K
ZSANQ
Zosano Pharma Corp
13 May 22
Zosano Pharma Reports First Quarter 2022 Financial Results
4:06pm
8-K
ZSANQ
Zosano Pharma Corp
5 May 22
Departure of Directors or Certain Officers
12:00am
8-K
zui3m3tgtviocsws y34
29 Apr 22
Zosano Pharma Provides Corporate Update
4:52pm
8-K
stl8ais98am72m9jp6
11 Apr 22
Zosano Pharma Announces Reverse Stock Split Effective Today
4:08pm
8-K
n7kxbgoaqtkpd2vo2
17 Mar 22
Zosano Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results
4:07pm
8-K
exfdl9d5xuf65la
18 Feb 22
Other Events
5:11pm
8-K
iaki7oqhu8vi3
9 Feb 22
Entry into a Material Definitive Agreement
5:21pm
8-K
55ac3ff
31 Jan 22
Other Events
9:45am
8-K
e2f9u6 rajlye56zl16q
24 Jan 22
Other Events
8:20am
8-K
u9p4vcflmvaxf8d1 r9
5 Jan 22
Other Events
9:22am
8-K
etp82jqpe9i5c
13 Dec 21
Departure of Directors or Certain Officers
4:32pm
8-K
t6r3na hez9npnjg3n4o
30 Nov 21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:07pm
8-K
yvszi5s
17 Nov 21
Zosano Pharma Announces the Successful Formulation of a COVID-19 Vaccine Candidate on its Microneedle Patch System
8:02am
8-K
hl35dcbw0
10 Nov 21
Zosano Pharma Reports Third Quarter 2021 Financial Results
4:18pm
8-K
1ppp8q s2h3
29 Oct 21
Other Events
5:13pm
8-K
btol8ryehr5ypln2zdas
6 Oct 21
Departure of Directors or Certain Officers
4:21pm
8-K
5jzc5r0w9
4 Oct 21
Zosano Pharma Granted Type C Meeting with FDA Regarding NDA Resubmission for M207 Following Preliminary Top-Line Pharmacokinetic Study Results
8:10am